On April 23, 2025 ImCheck Therapeutics reported an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2025, taking place from May 30 to June 3, in Chicago, Illinois, USA (Press release, ImCheck Therapeutics, APR 23, 2025, View Source [SID1234652062]). The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection data on the company’s lead γ9δ2 T-cell activator, ICT01, in combination with azacitidine and venetoclax for the treatment of older or unfit patients with newly diagnosed acute myeloid leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation at ASCO (Free ASCO Whitepaper) 2025 are:

Abstract Title: "γ9δ2 T-cell activation with ICT01 combined with azacitidine-venetoclax for older/unfit adults with newly diagnosed AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION"

Session: Oral Abstract Session S100a – Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant

Date: Monday, June 2, 2025

Time: 5:12 p.m.- 5:24 p.m. Central Time

The ASCO (Free ASCO Whitepaper) presentation will be available on ImCheck’s corporate website after the presentation has been held.